Clinical concentrations of volatile anesthetics (VAs) produce unconsciousness in humans and inhibit various behaviors in C. elegans. Although in vitro studies have demonstrated reduction of neurotransmitter release by VAs, the molecular mechanism for "general anesthesia" at a behavioral level remains unknown. We approached this problem by studying C. elegans mutants in two ways: behavioral inhibition and aldicarb resistance. Aldicarb is a specific acetylcholinesterase inhibitor that produces paralysis due to excess acetylcholine at the neuromuscular junction. We reasoned that should VAs such as halothane inhibit behavior by decreasing synaptic vesicle realease, they should also confer resistance to aldicarb's paralyzing effects, much like various loss-of-function mutations in presynaptic genes do. We tested in the aldicarb assay 30 strains carrying mutations in 22 different genes that might be involved in neurotransmitter release. The various strains were also tested for their VA sensitivity in a radial dispersal assay, which measures VA-induced loss of coordinated movement, and as such is a general measure of VA potency in C. elegans. One strain,
unc-64(
md130), proved to be highly resistant to VA effects on coordinated movement, as measured by the dispersal assay. Four strains were found to be significantly hypersensensitive to VAs by the same coordination assay (
ric-4 (
md1088),
snb-1(
md247),
unc-64(
js21),
unc-64(
md1259)). Thus,
unc-64, a syntaxin homologue, showed highly divergent effects (thirty-fold) on anesthetic potency depending on the specific allele. All of the syntaxin mutants, however, are aldicarb resistant and hence defective in neurotransmitter release. As expected for a presynaptic action of VAs, we found that exposure to the VAs halothane or isoflurane confers resistance to aldicarb in the N2 strain; the anesthetic in effect makes the worms "wake up" from aldicarb paralysis. The drug-induced aldicarb resistance peaks in exactly the same concentration range as that required to anesthetize a human (0.2 - 0.5 vol % halothane, for example) and to cause uncoordination in C. elegans. When tested by our aldicarb assay, the VA resistant strain,
unc-64(
md130), was impervious to halothane's awakening effects; the syntaxin mutation blocked VA-induced resistance to aldicarb. Paralysis due to levamisole, an acetylcholine receptor agonist, was also reversed, but to a lesser extent, in N2 by VAs. However,
md130 did not behave differently than N2 in the levamisole assay, suggesting that although VAs may act both pre and post-synaptically, the syntaxin mutation produces its effect on anesthetic sensitivity through a presynaptic mechanism. We tested whether the VA resistance phenotype was in fact due to the
md130 mutation by first mapping the resistance to within two map units of
bli-5, a closely linked mutation on III, and then by attempting to rescue
md130 anesthetic resistance with the wild-type plasmid coinjected with an
unc-54 driven GFP marker. Green
md130 transformants were indeed wild type for VA sensitivity, aldicarb sensitivity, and unc-ness. Altogether, these experiments show that a syntaxin loss-of-function mutation can confer resistance to volatile anesthetics as measured by two very different behavioral endpoints. These results suggest that volatile anesthetics act presynaptically, and that syntaxin is a candidate mediator of the action of Vas.